VaxCyte

Conjugate vaccines and protein-based vaccines

Also Clin2 65+ pneumococcal disease, Clin2 infant pneumococcal disease; VAX-XP Clin0 pneumococcal disease; VAX-A1 Clin0 strep infections; VAX-PG Clin0 periodontitis; VAX-GI Clin0 shigella

Vaxcyte is creating therapeutic vaccines to eliminate bacterial infections. Bacterial infections remain one of the greatest public health challenges, including infections caused by pneumococcal disease and periodontitis. Many emerging serotypes of pneumococcal disease are not covered by current vaccines. Vaxcyte aims to fix this problem by using their chemistry and cell-free protein synthesis platform (XpressCF) to engineer more effective vaccines. The valency of the vaccines is enhanced to offer precise, site-specific conjugation to immune epitopes. Vaxcyte’s lead candidate, VAX-24, is in Phase 2 clinical trials to be later used for pneumococcal disease with 3 other candidates in earlier stage development.

Jobs: